Forget GLP-1s—GLP-3s show promise in phase 3 weight loss and diabetes trial. Phase 3 clinical trial results (TRANSCEND-T2D-1) published in The Lancet report that retatrutide, an investigational once-weekly injection for diabetes management, can significantly improve blood sugar levels and lead to substantial weight loss in people with Type 2 diabetes.
A apuração publicada por medicalxpress.com vira base para uma leitura editorial direta e contextualizada.
Trechos de apoio da pauta: Phase 3 clinical trial results (TRANSCEND-T2D-1) published in The Lancet report that retatrutide, an investigational once-weekly injection for diabetes management, can significantly improve blood sugar levels and lead to substantial weight loss in people with Type 2 diabetes. The study included adults with Type 2 diabetes who were not taking diabetes medicines and whose blood sugar was not adequately controlled with diet and exercise alone.
- Ponto de atenção: forget.
- Ponto de atenção: show.
- Ponto de atenção: promise.
Em resumo, a leitura editorial acompanha o impacto do tema no nicho Fitness.
